Full Press Release Details
Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company
committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting
of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701,
1118 BN Schiphol, the Netherlands.
and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice
of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration
for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
item on the agenda will be the proposed appointment of Mr. Steve Krognes as non- executive director and Chair of the Audit and Compliance
Committee of the Company's Board of Directors.
for the meeting, as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available
for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage
shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
of Mr. Krognes, Werner Lanthaler will resign as non-executive director of the Board and Chair of the Audit and Compliance Committee to
enable this important step in the long term succession planning for the board of directors and the audit and compliance committee chairperson
role. The Company would like to express its gratitude towards Werner Lanthaler for his substantial contributions over the last eight
years. Werner's entrepreneurial nature combined with broad experience in finance, executive leadership, and life sciences has helped
guide argenx from a research- focused company to a fully integrated commercial-stage global immunology company.
immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic
researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio
of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker
in the U.S., Japan, and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several
Twitter, and Instagram.
information, please contact: